Inhibikase Therapeutics, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-6.1% -$237K
$-4M
Free Cash Flow
$0
Investing Cash Flow↑+287.1% +$7M
$10M
Financing Cash Flow↑+8.9% +$9M
$109M
Capex
$0
Stock-Based Comp↓-42.7% -$3M
$5M
D&A↓-100.0% -$26K
$0
SBC Allocated Expense↓-42.7% -$3M
$5M